Norges Bank
VERV

Norges Bank’s Verve Therapeutics VERV Stock Holding History

Norges Bank’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-78,186
Closed -$441K – 1855
2024
Q4 		$441K Hold
78,186
– – ﹤0.01% 1800
2024
Q3 		$378K Hold
78,186
– – ﹤0.01% 1807
2024
Q2 		$382K Buy
+78,186
New +$491K ﹤0.01% 1893

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Norges Bank's VERV Position: Q1 2025 in Review

Norges Bank sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 78,186 shares — an estimated $441K sold.

Norges Bank first reported a position in VERV in Q2 2024 and held it in 3 quarters. The position peaked at $441K in Q4 2024. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Norges Bank reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Norges Bank sold 78,186 Verve Therapeutics shares in Q1 2025, an estimated $441K.
  • Norges Bank first reported a position in Verve Therapeutics in Q2 2024 and held it in 3 quarters.
  • Norges Bank's Verve Therapeutics position peaked at $441K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.